144 related articles for article (PubMed ID: 21682816)
1. Three cases of schizophrenia showing improvement after switching to blonanserin.
Kurotaki N; Nobata H; Nonaka S; Nishihara K; Ozawa H
Psychiatry Clin Neurosci; 2011 Jun; 65(4):396-7. PubMed ID: 21682816
[No Abstract] [Full Text] [Related]
2. Blonanserin in the treatment of delirium.
Kato K; Yamada K; Maehara M; Akama F; Kimoto K; Saito M; Yano H; Ichimura A; Matsumoto H
Psychiatry Clin Neurosci; 2011 Jun; 65(4):389-91. PubMed ID: 21569175
[TBL] [Abstract][Full Text] [Related]
3. Iloperidone for schizophrenia.
Rado J; Janicak PG
Expert Opin Pharmacother; 2010 Aug; 11(12):2087-93. PubMed ID: 20586713
[TBL] [Abstract][Full Text] [Related]
4. Ziprasidone (Geodon) for schizophrenia.
Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
[No Abstract] [Full Text] [Related]
5. [Blonanserin in the treatment of schizophrenia].
Tenjin T; Miyamoto S
Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
[TBL] [Abstract][Full Text] [Related]
6. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
Kawabe K; Horiuchi F; Ueno S
Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
[TBL] [Abstract][Full Text] [Related]
7. Blonanserin, an antipsychotic and dopamine D₂/D₃receptor antagonist, and ameliorated alcohol dependence.
Takaki M; Ujike H
Clin Neuropharmacol; 2013; 36(2):68-9. PubMed ID: 23503552
[TBL] [Abstract][Full Text] [Related]
8. Focus on ziprasidone.
Green B
Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
[TBL] [Abstract][Full Text] [Related]
9. Schizophrenia: an illness of distorted reality.
Dean B
Biologist (London); 2000 Sep; 47(4):202-6. PubMed ID: 11153121
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1361-2. PubMed ID: 20647025
[No Abstract] [Full Text] [Related]
11. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Yang J; Bahk WM; Cho HS; Jeon YW; Jon DI; Jung HY; Kim CH; Kim HC; Kim YK; Kim YH; Kwon JS; Lee SY; Lee SH; Yi JS; Yoon BH; Kim SH
Clin Neuropharmacol; 2010 Jul; 33(4):169-75. PubMed ID: 20661022
[TBL] [Abstract][Full Text] [Related]
12. Delusional parasitosis presenting as folie à trois: successful treatment with risperidone.
Friedmann AC; Ekeowa-Anderson A; Taylor R; Bewley A
Br J Dermatol; 2006 Oct; 155(4):841-2. PubMed ID: 16965440
[No Abstract] [Full Text] [Related]
13. The position of blonanserin as a treatment for schizophrenia.
Kishi T; Matsuda Y; Iwata N
Asia Pac Psychiatry; 2014 Dec; 6(4):462. PubMed ID: 25425069
[No Abstract] [Full Text] [Related]
14. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
15. Quetiapine-induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.
Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
Psychiatry Clin Neurosci; 2012 Oct; 66(6):534-5. PubMed ID: 23066773
[No Abstract] [Full Text] [Related]
16. Pathophysiology of schizophrenia and the role of newer antipsychotics.
Risch SC
Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681
[TBL] [Abstract][Full Text] [Related]
17. Olfactory reference syndrome treated by blonanserin augmentation.
Takekita Y; Kato M; Sakai S; Suwa A; Nishida K; Tajika A; Yoshimura M; Kinoshita T
Psychiatry Clin Neurosci; 2011 Mar; 65(2):203-4. PubMed ID: 21414096
[No Abstract] [Full Text] [Related]
18. [Risperidone].
Zolk O; Thürauf N
Dtsch Med Wochenschr; 2003 Jun; 128(24):1353-6. PubMed ID: 12802745
[No Abstract] [Full Text] [Related]
19. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
Nasrallah HA; Fedora R; Morton R
Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203
[TBL] [Abstract][Full Text] [Related]
20. Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient.
Yoshida K; Higuchi H; Hishikawa Y
Clin Neuropharmacol; 1998; 21(1):68-9. PubMed ID: 9579290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
